Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04126278 · ClinicalTrials.gov registry record · Phase 4
Calcific Tendonitis Treatment: Barbotage vs. Barbotage With Cortisone Injection
A Phase 4 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT04126278 is a Phase 4 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 4 participants.
The verdict
NCT04126278, a Phase 4 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of barbotage therapy by comparing the clinical and sonographic changes in patients that solely receive barbotage to patients receiving the standard of care, barbotage with cortisone injection.
Interventions
- DRUG Dexamethasone
- DRUG Barbotage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2022-08-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04126278
The ClinicalTrials.gov registry entry for NCT04126278 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT04126278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04126278 about?
NCT04126278 is a clinical study titled "Calcific Tendonitis Treatment: Barbotage vs. Barbotage With Cortisone Injection". The purpose of this study is to determine the efficacy of barbotage therapy by comparing the clinical and sonographic changes in patients that solely receive barbotage to patients receiving the standard of care, barbotage with cortisone injection.
What is the current status of trial NCT04126278?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2020-12-01. Estimated completion is 2022-08-23.
What interventions are being tested in trial NCT04126278?
The interventions under investigation include: Dexamethasone (DRUG), Barbotage (DRUG).
Who is sponsoring clinical trial NCT04126278?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.